Holen Sie sich die Stockscreener-App
0.1703
5.25%
0.0085
Handel nachbörslich:
.17
-0.0003
-0.18%
Schlusskurs vom Vortag:
$0.1618
Offen:
$0.1599
24-Stunden-Volumen:
1.02M
Relative Volume:
1.41
Marktkapitalisierung:
$6.79M
Einnahmen:
$94,000
Nettoeinkommen (Verlust:
$-13.28M
KGV:
-0.0233
EPS:
-7.2965
Netto-Cashflow:
$-11.67M
1W Leistung:
-5.18%
1M Leistung:
-20.27%
6M Leistung:
-68.79%
1J Leistung:
-93.57%
1-Tages-Spanne:
$0.1599
$0.1756
1-Wochen-Bereich:
$0.1599
$0.183
52-Wochen-Spanne:
$0.1599
$2.8771
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.1703 | 6.79M | 94,000 | -13.28M | -11.67M | -7.2965 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech Highlights Recent Media Coverage of - GlobeNewswire
AIM ImmunoTech Highlights Recent Media Coverage of - GlobeNewswire
AIM ImmunoTech Spotlights Growing Attention Around - GlobeNewswire
57 patients with stable pancreatic cancer received an immune-modulating drug after chemotherapy. - Stock Titan
AIM ImmunoTech Spotlights Growing Attention Around - GlobeNewswire
AIM ImmunoTech Discusses Ampligen®’s Potential to - GlobeNewswire
AIM ImmunoTech Announces Virtual 2026 Annual Stockholders Meeting and Proxy Details - Kalkine Media
AIM ImmunoTech Submits 2025 Annual Report Highlighting Focus on Ampligen for Pancreatic Cancer - Kalkine Media
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video - The Manila Times
A 39-patient exploratory analysis reported 34.8 months’ median survival in pancreatic cancer. - Stock Titan
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib - markets.businessinsider.com
AIM Looks 71.3% Undervalued on GF Value™ Despite Financial Strug - GuruFocus
AIM ImmunoTech Highlights Ampligen’s Potential Role in the - globenewswire.com
AIM ImmunoTech Inc Share PriceAIM, RNS News, Articles, Quotes, & Charts (AMEX:AIM) - Proactive financial news
Aim Immunotech Stock Price Forecast. Should You Buy AIM? - StockInvest.us
Aim ImmunoTech CEO Equels buys $4,992 in stock - Investing.com
Aim ImmunoTech CEO & president buys $2,310 in company stock - Investing.com
Aim ImmunoTech CEO & President Thomas Equels buys $4,862 in stock - Investing.com
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements - The Globe and Mail
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements - TipRanks
AIM ImmunoTech Converts ~$450,000 of Note Into 1.92M Shares in Exchanges With Streeterville - TradingView
AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire
AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video - Yahoo Finance
AIM ImmunoTech Eliminates $1.22 Million Debt via Stock Exchange - minichart.com.sg
AIM ImmunoTech Extinguishes Debt Through Equity Exchanges - TipRanks
AIM ImmunoTech Secures Ampligen Patent Protection in Europe - Intellectia AI
AIM ImmunoTech Significantly Expands Ampligen® Global - GlobeNewswire
AIM ImmunoTech Significantly Expands Ampligen® Global - GlobeNewswire
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - The Manila Times
AIM ImmunoTech Secures European and U.K. Patent Protection for Ampligen in Long COVID Through 2041 - Quiver Quantitative
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - Yahoo Finance
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - GlobeNewswire
AIM ImmunoTech Extends IP Protection for Ampligen Through 2039 with Broad US Patent - Contract Pharma
AIM Looks 69.6% Undervalued on GF Value™ Despite Financial Distr - GuruFocus
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 - The Manila Times
AIM ImmunoTech Secures U.S. Patent for Ampligen Combination with Pembrolizumab in Cancer Treatment - Quiver Quantitative
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod - GlobeNewswire
AIM patent covers Ampligen with Keytruda across cancers through 2039 - Stock Titan
AIM Q2 2026 Earnings: Wider Than-Expected Loss as Clinical-Stage Costs PersistProfit Inflection Point - vinanet.vn
AIM ImmunoTech Inc. (AIM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
AIM ImmunoTech Inc. (AIM) Key Financial Ratios – Valuation, Profitability & More - Value Research
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - manilatimes.net
AIM ImmunoTech doses final patient in pancreatic cancer trial - stocktitan.net
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - Yahoo Finance
AIM ImmunoTech Participates in the Virtual Investor 'Why Now' On-Demand Conference - Moomoo
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - GlobeNewswire
AIM | AIM ImmunoTech Inc. FinancialsRevenue Breakdown - quiverquant.com
AIM ImmunoTech (AIM) Stock Forecast & Analyst Ratings - Moomoo
AIM Maintained by Ascendiant Capital -- Price Target Lowered to $7.00 - GuruFocus
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
AIM ImmunoTech Inc-Aktie (AIM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Equels Thomas K | CEO & President |
Sep 16 '26 |
Buy |
0.21 |
11,000 |
2,310 |
102,822 |
| Equels Thomas K | CEO & President |
Sep 15 '26 |
Buy |
0.22 |
22,000 |
4,862 |
91,822 |
| Equels Thomas K | CEO & President |
Sep 14 '26 |
Buy |
0.22 |
5,900 |
1,292 |
69,822 |
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):